Anxiety disorders are the most common of the psychiatric disorders and are also associated with significant economic costs and impaired work productivity. The first-line pharmacotherapy of pharmatherapy for a number of anxiety disorders comprises selective serotonin re-uptake inhibitors (SSRIs) and serotonin and noradrenaline re-uptake inhibitors (SNRIs). Benzodiazepines are still widely used for the treatment of several anxiety disorders. Although these agents are effective, many patients are treatment-refractory and more effective, better tolerated medications are required. This paper discusses the understandings of mechanisms involved in the anxiety disorders and reviews emerging medications. Mechanisms underlying the use of d-cycloserine, second generation antipsychotics and beta-blockers are particularly exciting.
Emerging anxiolytics. Publishing Authors By Initials
Chemical & Substance for Abstract: Emerging anxiolytics. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Emerging anxiolytics.
AFFILIATION: University of Cape Town, Department of Psychiatry, Faculty of Health Sciences, Anzio Road, Observatory 7925, South Africa. nirvana.pillay@gmail.com